UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: nash

Drug Development for NASH with Fibrosis: Expedited Programs

George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.

Read More

What does international collaboration mean for you?

The present COVID-19 crisis has demonstrated the vital need for knowledge sharing across the global science community. We asked three of our speakers what international collaboration means for them as leaders in their fields.

Read More

An Overview of Available Preclinical Models for Non-alcoholic Fatty Liver Disease

NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC)  the second most common cause of cancer deaths worldwide. Understanding the aetiology of NAFLD progression, developing non-invasive diagnostic tests and developing treatments are urgent priorities.

Read More

Understanding the gut-liver axis: implications for NAFLD prevention and treatment

You may have heard; humans are superorganisms. The human large intestine harbors tens of trillions of microbes, which equates to roughly 2 kg of cells. For reference, that’s how much your brain weighs! Within the gut microbiome, it is estimated that there are over 1,000 different species of bacteria.

Read More

Novel biomarkers and the development of a point-of-care test for fatty liver disease

Ahead of The 3rd Global NASH Congress, Dr Bevin Gangadharan explains how he helped to discover novel NAFLD biomarkers and their role in the development of a point-of-care test for NAFLD.

Read More

Screening for NAFLD in primary care: a preventative wonder or are we barking up the wrong tree?

The burden of chronic liver disease has a substantial health and economic burden within the UK. Chronic liver disease is the fifth most common cause of death in the UK and of those five, it is the only one with numbers that are rising. With this in mind, it would make sense that earlier detection of liver disease in primary care is key to improving outcomes and reducing costs.

Read More

Developing successful treatments for HCC and NASH

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second most common cause of cancer deaths worldwide.[1] There is not currently a successful therapy to treat HCC in advanced stages.[2] NASH is a primary risk factor for liver cancer.

Devanand Sarkar and his team have uncovered the molecular mechanisms leading to NASH and HCC, shedding light on the connections between obesity and cancer. He is leveraging this knowledge to develop targeted treatments for both NASH and advanced HCC. We asked him to give us a brief insight into his work ahead of his presentation at the 3rd Global NASH Congress, 2020.

Read More

Understanding the Role of the Gut Microbiome in NAFLD

NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive